These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 29129400)

  • 1. Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65.
    Linscott JA; Smith AB; Sammon JD
    Eur Urol; 2018 Apr; 73(4):e102-e103. PubMed ID: 29129400
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65.
    Choi W; McConkey D
    Eur Urol; 2018 Apr; 73(4):e104-e105. PubMed ID: 29174465
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66:609-10.
    Aine M; Liedberg F; Sjödahl G; Höglund M
    Eur Urol; 2015 Apr; 67(4):e73-5. PubMed ID: 25194907
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, and Mattias Höglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66:609-10.
    McConkey D; Choi W; Dinney C
    Eur Urol; 2015 Apr; 67(4):e76-8. PubMed ID: 25199718
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Panebianco V; Del Giudice F; Narumi Y; Simone G; De Berardinis E; Catto JWF
    Eur Urol; 2021 Feb; 79(2):e52-e53. PubMed ID: 33261940
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer?
    Vila-Reyes H; DeCastro GJ; McKiernan JM
    Eur Urol; 2021 Jan; 79(1):e35-e36. PubMed ID: 32829975
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6.
    Li R; Jain RK; Sexton WJ
    Eur Urol; 2021 Oct; 80(4):e99. PubMed ID: 34364728
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306.
    Panebianco V; Barentsz J; Narumi Y; Catto J;
    Eur Urol; 2018 Nov; 74(5):e109. PubMed ID: 30029821
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43.
    Bai Y; Yang Y; Tang Y
    Eur Urol; 2020 Jun; 77(6):e158. PubMed ID: 32199681
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6.
    Yang Y; Wei X; Han P
    Eur Urol; 2019 Aug; 76(2):e33. PubMed ID: 31054785
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636-43.
    Bandini M; Necchi A
    Eur Urol; 2020 Jun; 77(6):e159-e160. PubMed ID: 32184002
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
    Lamm D; Böhle A; Palou J; Persad R; Brausi M; Colombel M; Akaza H; Buckley R
    Eur Urol; 2010 Feb; 57(2):e7-9; author reply e10-1. PubMed ID: 19914768
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol;2020:533-7.
    Liedberg F; Eriksson P; Sjödahl G;
    Eur Urol; 2020 Dec; 78(6):e228-e229. PubMed ID: 33004248
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Paula M.J. Moonen, Judith M.J.E. Bakkers, Lambertus A.L.M. Kiemenay et al. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2007;52:464-9.
    Cai T; Mazzoli S; Mondaini N; Bartoletti R
    Eur Urol; 2008 Apr; 53(4):858-9; author reply 859. PubMed ID: 17920185
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
    Aldemir M; Canda AE; Balbay MD
    Eur Urol; 2010 Aug; 58(2):e23; author reply e24-5. PubMed ID: 20542629
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.
    Van Allen EM; Garraway LA; Rosenberg JE
    Eur Urol; 2015 Aug; 68(2):e31-2. PubMed ID: 25770487
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6.
    Li R; Spiess PE; Gilbert SM; Necchi A
    Eur Urol; 2019 Aug; 76(2):e34. PubMed ID: 31056228
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4.
    Lu M; Zhang Y; Xiao Y
    Eur Urol; 2019 Nov; 76(5):e135-e136. PubMed ID: 31420251
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4: Can Patient-derived Cancer Models Change the Costliest Cancer Type?
    Liu X
    Eur Urol; 2020 Jan; 77(1):e21-e22. PubMed ID: 31564577
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Fredrik Liedberg, Pontus Eriksson, and Gottfrid Sjödahl's Letter to the Editor re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol;2020:533-7.
    Meeks JJ; Dyrsjkøt L; Robertson AG
    Eur Urol; 2020 Dec; 78(6):e230-e231. PubMed ID: 32994066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.